Iovance Biotherapeutics, Inc. IOVA Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s cash ratio?
- Iovance Biotherapeutics, Inc. (IOVA) reported cash ratio of 1.5× in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s cash ratio changed year-over-year?
- Iovance Biotherapeutics, Inc.'s cash ratio increased by 8.5% year-over-year, from 1.4× to 1.5×.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s cash ratio has grown at a -0.8% compound annual growth rate (CAGR), from 1.2× to 1.2×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.